CompletedNot Applicable

Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

China463 participantsStarted 2017-11-30

Plain-language summary

Observational medical record review of newly diagnosed CML-CP participants in China

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ph+ CML-CP patients who were diagnosed between August 1, 2014 to August 1, 2016 * 18 years or older at time of diagnosis Exclusion Criteria: * Participants once enrolled in any interventional clinical trial for CML * Participants whose records are not available Other protocol defined inclusion/exclusion criteria could apply

What they're measuring

Number of participants receiving each first-line treatment option

Timeframe: 2 years

Number of participants with complete cytogenetic response

Timeframe: 2 years

Number of participants with major molecular response (MMR)

Timeframe: 2 years

Number of participants of each initial dose schema

Timeframe: 2 years

Starting dose of each first-line agent

Timeframe: 2 years

Trial details

NCT IDNCT03509896

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-06-07

View on ClinicalTrials.gov More Chronic Myeloid Leukemia trials